Literature DB >> 12461499

A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis.

Hema Patel1, Robert W Platt, Gary S Pekeles, Francine M Ducharme.   

Abstract

OBJECTIVE: In previously well infants hospitalized with acute viral bronchiolitis, the effectiveness of repeated nebulized therapy with epinephrine (EPI) was compared with treatment with albuterol (ALB) or saline placebo (PLAC). STUDY
DESIGN: In this randomized, double-blind, parallel-group, controlled trial, infants received study nebulizations every 1 to 6 hours and were assessed twice daily by the research team. The primary outcome was length of hospital stay (LOS). Secondary outcomes included the time from admission until the infant had normal hydration, oxygenation, and minimal respiratory distress.
RESULTS: A total of 149 infants were randomized; 50 were allocated to receive racemic EPI, 51 were given ALB, and 48 received PLAC. Baseline characteristics and pre-enrollment symptoms, signs, and therapy were similar between groups. There were no group differences in the primary outcome measure, mean LOS (hours)(+/- SD): EPI = 59.8 (62), ALB = 61.4 (54), and PLAC = 63.3 (47); P =.95 by intent-to-treat analysis. Group differences were not statistically significant in any of the secondary outcomes.
CONCLUSIONS: There were no group differences in the effectiveness of therapy for infants hospitalized with bronchiolitis. Based on these results, we do not recommend routine use of either nebulized EPI or ALB in this patient group.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12461499     DOI: 10.1067/mpd.2002.129844

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

1.  Paediatric emergency research in Canada: Using the iterative loop of research as a paradigm for advancing the field.

Authors:  David W Johnson; Martin H Osmond; Nicola Hooton; Terry P Klassen
Journal:  Paediatr Child Health       Date:  2004-07       Impact factor: 2.253

2. 

Authors:  Teeranai Sakulchit; Ran D Goldman
Journal:  Can Fam Physician       Date:  2016-12       Impact factor: 3.275

Review 3.  Systematic review of instruments aimed at evaluating the severity of bronchiolitis.

Authors:  Carlos E Rodriguez-Martinez; Monica P Sossa-Briceño; Gustavo Nino
Journal:  Paediatr Respir Rev       Date:  2017-02-15       Impact factor: 2.726

Review 4.  Bronchodilators for bronchiolitis.

Authors:  Anne M Gadomski; Melissa B Scribani
Journal:  Cochrane Database Syst Rev       Date:  2014-06-17

5.  Nebulized epinephrine for young children with bronchiolitis.

Authors:  Teeranai Sakulchit; Ran D Goldman
Journal:  Can Fam Physician       Date:  2016-12       Impact factor: 3.275

6.  Comparison of epinephrine to salbutamol in acute bronchiolitis.

Authors:  Mohammad-Reza Modaressi; Asadola Asadian; Jamal Faghihinia; Mehrshad Arashpour; Firoozeh Mousavinasab
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

7.  The use of C-reactive protein in predicting bacterial co-Infection in children with bronchiolitis.

Authors:  Mohamad Fares; Sawsan Mourad; Mariam Rajab; Nahida Rifai
Journal:  N Am J Med Sci       Date:  2011-03

8.  Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076].

Authors:  Joanne M Langley; Michael B Smith; John C LeBlanc; Heather Joudrey; Cecil R Ojah; Paul Pianosi
Journal:  BMC Pediatr       Date:  2005-05-05       Impact factor: 2.125

9.  Comparison of nebulized epinephrine to albuterol in bronchiolitis.

Authors:  Paul Walsh; John Caldwell; Kemedy K McQuillan; Steven Friese; Dale Robbins; Stephen J Rothenberg
Journal:  Acad Emerg Med       Date:  2008-04       Impact factor: 3.451

10.  Epinephrine Improves the Efficacy of Nebulized Hypertonic Saline in Moderate Bronchiolitis: A Randomised Clinical Trial.

Authors:  J Carlos Flores-González; Miguel A Matamala-Morillo; Patricia Rodríguez-Campoy; Juan J Pérez-Guerrero; Belén Serrano-Moyano; Paloma Comino-Vazquez; Encarnación Palma-Zambrano; Rocio Bulo-Concellón; Vanessa Santos-Sánchez; Alfonso M Lechuga-Sancho
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.